NCT01467583View on ClinicalTrials.gov

Fondaparinux in Critically Ill Patients With Renal Failure

PHASE4CompletedINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions

Venous Thromboembolism

Interventions

DRUG

Fondaparinux

2.5 mg every 48 hours

Trial Locations (1)

48201

Detroit Medical Center, Detroit

Sponsors

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

lead

Wayne State University

OTHER

NCT01467583 - Fondaparinux in Critically Ill Patients With Renal Failure | Biotech Hunter | Biotech Hunter